In mid-October, the Russian Ministry of Health approved clinical trials of a nasal spray form of the Sputnik V vaccine developed by the Gamaleya Center, according to RIA Novosti. Gamaleya is still testing the efficacy of the nasal vaccine, according to the deputy director of Gamaleya, Denis Logunov. "I must confess it is an off-label administration basically, as usual, we are testing it on our employees," Logunov told Putin in a televised conversation after administering the booster on Sunday. Putin responded by asking Logunov
whether he could "take part in this experiment."
Logunov said the intranasal form was developed in order to "induce barrier immunity," which with Covid-19, "refers to our immune organs located in the nose and the pharynx." "We also know that vaccines administered through parenteral method, or intramuscular injection, are effective, but they have limited ability to induce immunity from so-called breakthrough infection and symptomatic illness. We need to deliver the agent through the mucous membranes to induce barrier immunity."
whether he could "take part in this experiment."
Logunov said the intranasal form was developed in order to "induce barrier immunity," which with Covid-19, "refers to our immune organs located in the nose and the pharynx." "We also know that vaccines administered through parenteral method, or intramuscular injection, are effective, but they have limited ability to induce immunity from so-called breakthrough infection and symptomatic illness. We need to deliver the agent through the mucous membranes to induce barrier immunity."
